- Citations, last 5 years
- 147
- Works, last 5 years
- 20
- h-index
- 32
- Scientists listed
- 2
- Grants since 2016
- 11
Grants received
2024–2026 · research · R44
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
Frank H. Ebetino · BioVinc (United States) · funded by National Institutes of Health
2024–2027 · research · R44
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
Frank H. Ebetino · BioVinc (United States) · funded by National Institutes of Health
2023–2024 · research · R44
A Novel Bone Targeted Antibiotic Therapy for the Treatment of Infected Fractures
Frank H. Ebetino · BioVinc (United States) · funded by National Institutes of Health
2019–2022 · research · R41
Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer
Kai Chen · BioVinc (United States) · funded by National Institutes of Health
2018–2022 · research · R44
Competitive Equilibrium-based Displacement of Bisphosphonates as Novel Therapeutic Approach for BRONJ
Frank H. Ebetino · BioVinc (United States) · funded by National Institutes of Health
2018–2021 · research · R43
Bone targeted antimicrobials for the treatment of diabetic foot related infections and osteomyelitis
Frank H. Ebetino · BioVinc (United States) · funded by National Institutes of Health
2016–2021 · research · R42
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment
Frank H. Ebetino · BioVinc (United States) · funded by National Institutes of Health
2016–2023 · research · R44
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy
Frank H. Ebetino · BioVinc (United States) · funded by National Institutes of Health
2016–2019 · research · R42
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment
Frank H. Ebetino · BioVinc (United States) · funded by National Institutes of Health
2016–2018 · research · R41
Bone targeted antimicrobials for biofilm-mediated osteolytic infection treatment
Frank H. Ebetino · BioVinc (United States) · funded by National Institutes of Health
2016–2022 · research · R44
Bone targeted delivery of an antimicrobial drug for osteomyelitis therapy
Frank H. Ebetino · BioVinc (United States) · funded by National Institutes of Health